Off-Label Use of Antipsychotic Agents in Dementia: Evidence for the Revision of the Reimbursement Policy

Abstract

Background:

Harmonized requirements apply for the marketing authorization of medicinal products in the EU Member States. On the contrary, the national legislations on the drug reimbursement are not harmonized. The aim of this study was to find out if they are robust enough to ensure high standards of public health protection with focus on the symptomatic treatment of dementia in the elderly.

Methods:

A computerized search of authorized therapeutic indications of haloperidol and trihexyphenidyl in the national databases of 8 EU member states and an analysis of the national legislation on reimbursement policies in Lithuania and Latvia was performed.

Results:

There is a discrepancy in the decisions on the marketing authorization vs the reimbursement in Lithuania and Latvia (reimbursement of haloperidol and trihexyphenidyl for the off-label treatment of dementia).

Conclusions:

National legislation on the drug reimbursement in Lithuania and Latvia does not provide safeguards for public health at the same level as the marketing authorization does. Absence of a revision of former decisions in the light of new evidence is a critical weakness of the drug reimbursement in Lithuania and Latvia. Reimbursement for the off-label indications may pose a risk to public health.

Keywords

reimbursement policy off-label use dementia benefit-risk ratio

Get full access to this article

View all access options for this article.

References

Directive 2001/83/EC of the European Parliament and of the Council of 6 Nov 2001 on the Community code relating to medicinal products for human use. Official Journal L 311. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf. Published November 28, 2001. Accessed July 25, 2018.

Order on the change of the lists of diseases, reimbursed medicinal products for their treatment, reimbursed medicines and medicinal devices approved by the Decree of the Minister of Health of Lithuania No 159, 5 April 2002 including amendments. Valstybės žinios 2002, Nr. 39-1450; https://www.e-tar.lt/portal/lt/legalAct/TAR.E83CFAB10E7B/mowqwUsGUT.

State Medicines Control Agency are under the Ministry of Health of the Republic of Lithuania. https://vapris.vvkt.lt/vvkt-web/public/medications?. Accessed February 24, 2018.

List of diseases and reimbursed medicines for their treatment approved by the Order of the Minister of Health of Lithuania No 49, 28 Jan 2000 as amended. Valstybės žinios 2000, Nr. 10-253. https://www.e-tar.lt/portal/lt/legalAct/TAR.FA9CC3E1430C/PAnzulvnKH.

List of reimbursable diagnoses, common names of medicines and medical devices (1 1, 2017). http://www.vmnvd.gov.lv/lv/kompensejamie-medikamenti/kompensejamo-zalu-saraksts. Accessed February 24, 2018.

Guideline on the diagnostics and treatment of the Alzheimer dementia. http://www.vlk.lt/veikla/veiklos-sritys/kompensuojamieji-vaistai/Documents/alzheimerio_diagnozavimo_gydymo_metodika.pdf approved by the Order of the Minister of Health of Lithuania No 382, 4 Jul 2000. Accessed June 25, 2018.

Tardy

Huhn

Kissling

Engel

Leucht

. Haloperidol versus first-generation low-potency antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2014;7:CD009268.

Wang

Schneeweiss

Avorn

. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353:2335–2341.

Schneider

Dagerman

Insel

. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934–1943.

10.

von Moltke

Abernethy

Greenblatt

. Kinetics and dynamics of psychotropic drugs in the elderly. In: Salzman

, ed. Clinical Geriatric Psychopharmacology. Vol. 4. Philadelphia, PA: Lippincott, Williams and Wilkins; 2005:87–114.

11.

FDA Public Health Advisory. Deaths with antipsychotics in elderly patients with behavioral disturbances. https://wayback.archive-it.org/7993/20170723113222/https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm053171.htm. Published April 11, 2005. Accessed June 25, 2018.

12.

Busko

. FDA requires conventional and atypical antipsychotics to warn of increased death risk in elderly dementia. https://www.medscape.com/viewarticle/576382. Published June 20, 2008. Accessed June 25, 2018.

13.

CHMP Assessment report on conventional antipsychotics, London, 20 November 2008 EMEA/CHMP/590557/2008. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/01/WC500054057.pdf. Accessed June 25, 2018.

14.

Keepers

Clappison

Casey

. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry. 1983;40:1113–1117.

15.

Kalisch Ellett

Pratt

Ramsay

Barratt

Roughead

. Multiple anticholinergic medication use and risk of hospital admission for confusion or dementia. J Am Geriatr Soc. 2014;62:1916–1922.

16.

Pasina

Djade

Lucca

. Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study. Drugs Aging. 2013;30:103–112.

17.

Medicinal Product Register of Latvia. https://www.zva.gov.lv/zalu-registrs/?lang=en. Accessed February 24, 2018.

18.

The electronic Medicines Compendium (eMC) on medicines licensed for use in the UK. https://www.medicines.org.uk/emc/. Accessed February 24, 2018.

19.

Deutsches Institut für Medizinische Dokumentation und Information. http://www.dimdi.de/static/de/amg/index.htm. Accessed February 24, 2018.

20.

Arzneispezialitätenregister. Bundesamt für Sicherheit im Gesundheitswesen Medizinmarktaufsicht; https://aspregister.basg.gv.at/aspregister/faces/aspregister.jspx?_afrLoop=47858239438131233&_afrWindowMode=0&_adf.ctrl-state=vtl1sdv8q_4. Accessed February 24, 2018.

21.

Vademecum.es. http://www.vademecum.es. Accessed February 24, 2018.

22.

Geneesmiddeleninformatiebank. http://www.geneesmiddeleninformatiebank.nl/ords/f?p=111:1:0::NO:SESSION:P0_DOMAIN,P0_LANG:H,NL. Accessed February 24, 2018.

23.

Agence nationale de sécurité du médicament et des produits de santé. Répertoire des Spécialités Pharmaceutiques. http://agence-prd.ansm.sante.fr/php/ecodex/index.php. Accessed February 24, 2018.

24.

Commission Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use. Official Journal L 159, 2003.06.27, pp. 46–94. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/dir_2003_63/dir_2003_63_en.pdf.

25.

le Polain

Franken

Koopmanschap

Cleemput

. Drug reimbursement systems: international comparison and policy recommendations. The Belgian Health Care Knowledge Centre report 147. https://kce.fgov.be/publication/report/drug-reimbursement-systems-international-comparison-and-policy-recommendations-0#.WL6HA_nyjDc. Published 2010.

26.

Daniels

Sabin

. Limits to health care: fair procedures, democratic deliberation, and the legitimacy problem for insurers. Philos Public Aff. 1997;26:303–350.

27.

Ballard

Waite

. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev 2006;1:CD003476.

28.

Schneider

Tariot

Dagerman

. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med. 2006;355:1525–1538.

29.

Wilson

Nutt

Alford

. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol. 2010;24:1577–1600.

30.

Ballard

Waite

. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1:CD003476.

31.

Douglas

Smeeth

. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ 2008;337:a1227.

32.

Sahlberg

Holm

Gislason

Køber

Torp-Pedersen

Andersson

. Association of selected antipsychotic agents with major adverse cardiovascular events and noncardiovascular mortality in elderly persons. J Am Heart Assoc. 2015;4(9):e001666.

33.

Schmedt

Kollhorst

Enders

. Comparative risk of death in older adults treated with antipsychotics: a population-based cohort study. Eur Neuropsychopharmacol. 2016;26:1390–1400.

34.

ATC DDD Index. WHO Collaborating Centre for Drug Statistics Methodology. Norwegian Institute of Public Health. https://www.whocc.no/.

35.

Pasina

Djade

Lucca

36.

Richter

Michel

Onur

. White matter lesions and the cholinergic deficit in aging and mild cognitive impairment. Neurobiol Aging. 2017;53:27–35.

37.

Liu

Zhu

Teipel

. White matter damage in the cholinergic system contributes to cognitive impairment in subcortical vascular cognitive impairment, no dementia. Front Aging Neurosci. 2017;9:47.